0.8kg 10mm DC12V Push SA-1192 Magnet Electromagnet Solenoid DC Frame Type Pull Other Electrical Equipment & Supplies


  1. Home
  2. 0.8kg 10mm DC12V Push SA-1192 Magnet Electromagnet Solenoid DC Frame Type Pull
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
DC12V 10mm 0.8kg Push Pull Type Frame DC Solenoid Electromagnet Magnet SA-1192
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is MPN:

Does Not Apply

Wire Length: 16cm/6.24" Brand:

Uxcell

Force: 0.8kg Main Color: Black
Net Weight: 300g Country of Manufacture: CHINA
Package Content: 1 x DC Solenoid Electromagnet Model:

SA-1192

Mounting Hole Size: 5 x 4mm/0.2" x 0.16"(L*W) Type: Push Pull
Voltage: DC 12V Stroke: 10mm
Body Size: 85 x 43 x 40mm/3.32" x 1.68" x 1.56"(L*W*H) Material: Metal & Electronic Parts
UPC:

609876050814




published on tue nov 09 2021

0.8kg 10mm DC12V Push SA-1192 Magnet Electromagnet Solenoid DC Frame Type Pull Other Electrical Equipment & Supplies

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

0.8kg 10mm DC12V Push SA-1192 Magnet Electromagnet Solenoid DC Frame Type Pull Other Electrical Equipment & Supplies

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS